The European Medicines Agency has updated information on critical pharmaceuticals Wezenla ustekinumab and Cejemly sugemalimab, impacting hospital procurement and patient care across Europe.

Merck partners with Mayo Clinic to leverage AI, advanced analytics, and multimodal clinical data for accelerating drug discovery and precision medicine initiatives.

US medical device firm Edwards Lifesciences has voluntarily terminated its controversial anti-copycat policy, thereby escaping a formal European Commission investigation impacting hospital procurement of cardiovascular devices.

Hospitals' mandated price postings under Trump policies are primarily utilized by insurers for contract negotiations rather than patient shopping, amid ongoing compliance issues and regulatory enhancements.

Apollo Hospitals Enterprise Limited achieved a 28% year-over-year increase in international patient revenues for Q3FY26, driven by diversification into new markets like Africa, West Asia, and Southeast Asia, offsetting declines from Bangladesh.[3]

Picard Medical will unveil first in vitro and in vivo evaluation data for SynCardia’s electromechanical total artificial heart on February 16, 2026, at the EUMS summit in Barcelona, advancing treatments for advanced heart failure.

Four Trinity Health hospitals in Michigan have initiated a program installing lifesaving Narcan vending machines to enhance community access amid the opioid crisis.

The Philippines' Asian Hospital and Medical Centre clinched Philippines Innovator of the Year - Healthcare and Philippines Team of the Year - Healthcare at the Asian Management Excellence Awards 2026 for its Asian Cancer Institute's operational successes and CyberKnife S7 deployment.

Tian Ruixiang Holdings enters strategic partnership and acquisition discussions with Singapore's top three medical technology leaders to integrate AI diagnostics into Asia-Pacific clinics, targeting 95%+ accuracy and 40%+ cost reductions.

The European MedTech and HealthTech sectors enter a phase of disciplined industrial maturity in February 2026, marked by regulatory pressures and surging M&A activity.